<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771988</url>
  </required_header>
  <id_info>
    <org_study_id>Y90-2-LT-15-01</org_study_id>
    <nct_id>NCT04771988</nct_id>
  </id_info>
  <brief_title>Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis</brief_title>
  <official_title>Trans-arterial Radioembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with hgepatocellular carcinoma (HCC) and portal vein tumoral thrombosis (PVTT),&#xD;
      Sorafenib represents the treatment of choice but more recently, trans-arterial&#xD;
      radioembolization (TARE) with yttrium-90 has been also proposed. A considerable percentage of&#xD;
      such patients are not only able to achieve stability of the disease, but also to obtain a&#xD;
      complete radiological response (CR). The possibility of achieving a CR might allow these&#xD;
      patients to be listed for liver transplantation (LT), in order to cure not only the cancer&#xD;
      but also the underlying cirrhosis that generated it.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2013</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 8, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response to radioembolization</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint of this study was to assess the effect of radioembolization in HCC patients with PVTT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>The secondary endpoint was overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>The secondary endpoint was progression-free survival (PFS)</description>
  </secondary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium-90 radioembolization</intervention_name>
    <description>selective/superselective treatment using resin microspheres labeled with Yttrium-90</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients diagnosed with HCC and PVTT presenting to our Institution&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. diagnosis of HCC;&#xD;
&#xD;
          2. age ≥ 18 years;&#xD;
&#xD;
          3. performance status according to Eastern Cooperative Oncology Group 0-1;&#xD;
&#xD;
          4. preserved liver function (Child-Pugh score ≤B7);&#xD;
&#xD;
          5. PVTT limited to the first order portal branch.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. any contraindication to TARE treatment;&#xD;
&#xD;
          2. macrovascular invasion extended to the main portal trunk and/or to the contralateral&#xD;
             portal branch;&#xD;
&#xD;
          3. presence of extra-hepatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>rita golfieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria di Bologna</affiliation>
  </overall_official>
  <results_reference>
    <citation>Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84(5):311-8. doi: 10.1159/000348325. Epub 2013 Apr 18. Review.</citation>
    <PMID>23615394</PMID>
  </results_reference>
  <results_reference>
    <citation>Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010 Jan;138(1):52-64. doi: 10.1053/j.gastro.2009.09.006. Epub 2009 Sep 18.</citation>
    <PMID>19766639</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Rita Golfieri</investigator_full_name>
    <investigator_title>Chief of Radiology Unit</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>macrovascular invasion</keyword>
  <keyword>portal vein thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

